Bicycle Therapeutics BCYC
NASDAQ BCYC
$3.60 +0.06 (+1.84%)
At close: Oct 20, 2026 · 4:00 PM EDT

Bicycle Therapeutics (BCYC) Short term Debt (2024)

Updated

Bicycle Therapeutics (BCYC) reported Short term Debt of $22.4 million for Q2 2024.

Analysis

Bicycle Therapeutics (BCYC) Short term Debt (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Bicycle Therapeutics 249.90 Mn -2.10 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 22.40 Mn
API Access

Bicycle Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=BCYC&period=max&api_key=YOUR_API_KEY